Joseph L Schuller, Mori J Krantz
Index: Expert Opin. Pharmacother. 13(13) , 1825-7, (2012)
Full Text: HTML
The most commonly prescribed class of medications in the United States for chronic severe pain is opioid analgesics. Due to their low cost and widespread availability, the synthetic opioids are popular choices among clinicians and patients. However, there is an increasingly recognized risk of QT prolongation with several drugs in this class, and recently propoxyphene (Darvon) was withdrawn from the market by the Food and Drug Administration (FDA) due to, in part, the risk of QT prolongation and ventricular arrhythmias Updated Epidemiological Review of Propoxyphene Safety. [FDA Alert]. Rockville, MD: U.S. Food and Drug Administration; 2010. Available from: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM234383.pdf on 5 May 2012 .
| Structure | Name/CAS No. | Molecular Formula | Articles | 
|---|---|---|---|
                        ![]()  | 
                    dextropropoxyphene
                     CAS:469-62-5  | 
                    C22H29NO2 | 
| 
                                
                                Clinical toxicology in Edinburgh, two centuries of progress.
                                 2013-07-01 [Clin. Toxicol. (Phila.) 51(6) , 509-14, (2013)]  | 
                        
| 
                                
                                Diplopia with dextropropoxyphene withdrawal.
                                 2013-02-01 [Gen. Hosp. Psychiatry 35(1) , 100-1, (2013)]  | 
                        
| 
                                
                                Urine drug testing of chronic pain patients. V. Prevalence o...
                                 2013-01-01 [J. Anal. Toxicol. 37(1) , 1-4, (2013)]  | 
                        
| 
                                
                                Physician perspective on propoxyphene as a potentially inapp...
                                 2011-07-01 [South. Med. J. 104(7) , 533-9, (2011)]  | 
                        
| 
                                
                                [Which analgesic after dextropropoxyphene withdrawal? A surv...
                                 2011-01-01 [Therapie. 66(1) , 25-8, (2011)]  | 
                        
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved
